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Abstract
Background: Patients with acute myocardial infarction and newly detected abnormal glucose regulation have
been shown to have a less favourable prognosis compared to patients with normal glucose regulation. The
importance and timing of oral glucose tolerance testing (OGTT) in patients with acute myocardial infarction
without known diabetes is uncertain. The aim of the present study was to evaluate the impact of abnormal
glucose regulation classified by an OGTT in-hospital and at three-month follow-up on clinical outcome in patients
with acute ST elevation myocardial infarction (STEMI) without known diabetes.
Methods: Patients (n = 224, age 58 years) with a primary percutanous coronary intervention (PCI) treated STEMI
were followed for clinical events (all-cause mortality, non-fatal myocardial re-infarction, recurrent ischemia causing
hospital admission, and stroke). The patients were classified by a standardised 75 g OGTT at two time points, first,
at a median time of 16.5 hours after hospital admission, then at three-month follow-up. Based on the OGTT results,
the patients were categorised according to the WHO criteria and the term abnormal glucose regulation was
defined as the sum of impaired fasting glucose, impaired glucose tolerance and type 2-diabetes.
Results: The number of patients diagnosed with abnormal glucose regulation in-hospital and at three-month was 105
(47%) and 50 (25%), respectively. During the follow up time of (median) 33 (27, 39) months, 58 (25.9%) patients
experienced a new clinical event. There were six deaths, 15 non-fatal re-infarction, 33 recurrent ischemia, and four
strokes. Kaplan-Meier analysis of survival free of composite end-points showed similar results in patients with abnormal
and normal glucose regulation, both when classified in-hospital (p = 0.4) and re-classified three months later (p = 0.3).
Conclusions: Patients with a primary PCI treated STEMI, without previously known diabetes, appear to have an
excellent long-term prognosis, independent of the glucometabolic state classified by an OGTT in-hospital or at
three-month follow-up.
Trial registration: The trial is registered at http://www.clinicaltrials.gov, NCT00926133.
Background
Patients hospitalised with acute myocardial infarction (MI)
have a reported incidence of known type 2 diabetes
between 10 and 20% [1]. Patients with type 2 diabetes and
acute MI have a higher incidence of new cardiovascular
events and higher in-hospital and long-term mortality rate
compared to non-diabetic patients [2-4]. In diabetic
patients with ST elevation myocardial infarction (STEMI),
primary percutaneous coronary intervention (PCI) with
adjunctive glycoprotein IIb/IIIa inhibition has been shown
to be associated with improved prognosis compared to
fibrinolytic treatment [5].
Several studies have reported that a substantial pro-
portion of patients with acute MI, without known type
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[6,7]. In addition, an increased risk of cardiovascular
morbidity and mortality has been demonstrated in
patients with acute MI and newly detected abnormal
glucose regulation [8], emphasizing the importance of
diagnosing these patients at an early stage. Accordingly,
the European guidelines on diabetes, pre-diabetes and
cardiovascular diseases from 2007 recommend that
these patients should be investigated with an oral glu-
cose tolerance test (OGTT) [9]. The timing and impor-
tance of broad OGTT screening after an acute MI are,
however uncertain, especially in patients subjected to
modern treatment with primary PCI resulting in smaller
infarct size and improved prognosis.
We have previously reported that patients with a pri-
mary PCI treated STEMI without known diabetes, have a
high prevalence of undetected abnormal glucose regula-
tion classified by an OGTT either in-hospital or three
months later [10]. However, when repeating an OGTT in
a stable condition at three-month follow-up the observed
reproducibility of the early test was poor, only 54% of the
patients remained in the same glucometabolic category
after a repeated OGTT. The OGTT performed early after
a STEMI did not provide reliable information on long-
term glucometabolic state [10].
An additional rationale for an early OGTT in patients
without known diabetes with a recent acute MI is to iden-
tify high-risk patients with poor prognosis. The aim of the
present study was to investigate clinical outcome in
patients with a primary PCI treated STEMI after exclusion
of patients with known diabetes. Secondly, to evaluate
whether abnormal glucose regulation classified by OGTT
acutely in-hospital or in a stable condition at three-month
follow-up was associated with poorer long-term prognosis
after acute STEMI.
Methods
Study population
Patients with an acute STEMI without known diabetes
admitted to the coronary care unit, Oslo University Hospi-
tal, Ullevål, Oslo, Norway were prospectively enrolled
from November 2005 to May 2007. The cohort is
described in detail elsewhere [10]. In brief, patients with a
primary PCI treated STEMI were included if they were
hemodynamically stable, without chest pain or nausea, age
< 85 years and with serum creatinine < 200 umol/L.
Patients with previously known type 2 diabetes, persistent
hyperglycaemia or clinical signs of heart failure were
excluded. Heart failure complicating acute MI was defined
according to the ESC Guidelines from 2008 [11]. Patients
with persistent hyperglycaemia were defined as patients
with both admission plasma glucose >11 mmol/L and a
fasting capillary glucose level > 8 mmol/L. A standardized
75 g OGTT (plasma glucose measurements at 0 and
120 min) was performed after an overnight fast [12]. Alto-
gether 224 patients were included. The inclusion date was
defined as the date when the primary PCI was performed.
Based on the result of the OGTT, the patients were
glucometabolically classified according to the WHO
guidelines from 2005 into one of the following cate-
gories [13] (glucose levels given in mmol/L):
Normal Glucose Tolerance (NGT) = OGTT (0 min) <
6.1 and OGTT (2 h) < 7.8
Impaired Fasting Glucose (IFG) = OGTT (0 min) ≥
6.1 <7.0 and OGTT (2 h) <7.8
Impaired Glucose Tolerance (IGT) = OGTT (0 min)
<7.0 and OGTT (2 h) ≥7.8 < 11.1
Type 2 diabetes (T2DM) = OGTT (0 min) ≥7.0 and/or
OGTT (2 h) ≥11.1.
The term abnormal glucose regulation was defined as
the sum of IFG, IGT and T2DM.
This was an observational study. The results of analyses
of blood glucose, either fasting or during OGTT were
available for the treating physician at all time. Hypergly-
caemia, if present, was treated at the physician’sd e c i s i o n
according to local, hospital practice. Patients were
returned back to the referring hospital with a hospital
record, which included information about the OGTT
results. The responsible physician was asked to perform
plasma glucose analyses repeatedly and start treatment if
indicated. A diagnosis of diabetes was not based on the
early OGTT performed during acute illness. The results of
the OGTT and fasting glucose value were communicated
to the general practitioners (GP) responsible for the
patient. If an asymptomatic patient were diagnosed with
type 2 diabetes at both occasions (in-hospital and at fol-
low-up) the GP was contacted by phone and asked to con-
firm the diagnosis and initiate lifestyle changes and
medical treatment according to national guidelines.
STEMI was defined according to the universal definition
of myocardial infarction as typical rise and fall of the car-
diac biomarker troponin T with at least one value above
the 99th percentile of the upper reference limit in patients
presenting with symptoms of ischemia together with new
ST elevation at the J-point in two contiguous leads with
the cut-off points: 0.2 mV in men or 0.15 mV in women
in leads V2-V3 and/or 0.1 mV in other leads or new left
bundle-branch block [14]. The median time from onset of
chest pain to balloon (PCI) was 219 minutes (140, 378).
The Regional ethics committee approved the study
and all patients provided written and oral informed
consent.
Laboratory methods
After overnight fasting, blood samples for routine analysis
including glucose and HbA1c were drawn and analysed by
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Troponin T (TnT) was measured by electrochemilumines-
cence technology for quantitative measurement (3
rd gen-
eration TnT, Elecsys 2010, Roche, Mannheim, Germany).
The lower detection limit of the assay is 0.01 ug/L with a
recommended diagnostic threshold of 0.03 ug/L. The
inter-assay coefficient of variation was 7%.
Insulin was measured by a competitive radioimmunoas-
say (RIA) kit (Linco Research, Inc, ST. Charles, MO, US)
and C-peptide was determined by Immulite 2000 (Diag-
nostic Product Corporation, Los Angeles, CA, US). Proin-
sulin was measured by an enzyme immunoassay (kit) from
DRG instruments (Gmbtt, Marburg. Germany). The
homeostasis model assessment of insulin resistance
(HOMA-IR) was calculated as fasting serum insulin (in
pmol/L) multiplied with fasting plasma glucose (in mmol/
L) and divided by 135 [15].
Follow up
At three-month follow-up, clinical examination and a
repeated OGTT were performed.
In addition, left-ventricular (LV) function and infarct
size were assessed at rest at follow-up. Perfusion imaging
was performed according to ECG-gated SPECT after
injection of
99m-tetrofosmin (Myoview™,A m e r s h a m
Health, UK). An Exeleris processing station (GE Medical
Systems) with 4D-MSPECT™ software (University of
Michigan), was used for processing of all recordings and
assessment LV volumes, LV ejection fraction (LVEF) and
infarct size (proportion perfusion defect) expressed as per-
cent of LV mass [16].
In June 2009, at a median follow up time of 33 months,
the patients were contacted and interviewed by telephone,
regarding their health status, and any hospital admissions.
Closing date was set to August 1st 2009. None of the
patients were lost to long-term follow-up, but only 201
patients attended the three-month follow-up examination.
In case of re-hospitalisation, hospital records were col-
lected from the patients’ community hospitals.
The primary endpoint of the study was defined as the
composite of the first event of non-fatal myocardial re-
infarction, recurrent ischemia causing hospital admission,
stroke, and all cause mortality. An end-point committee
classified the end-points according to the hospital records,
and death certificates were obtained from the Norwegian
Death Certificate Registry.
Statistics
Continuous variables are presented as median and 25, 75
percentiles and categorical variables as proportions. Due
to skewness in most of the measured variables, non-para-
metric statistics was used throughout. Differences among
groups were analysed by Mann-Whitney test for continu-
ous variables and the Chi square test for categorical data.
Univariate and multivariate analyses of this dynamic
cohort with censored data (Kaplan-Meier survival, Log-
Rank test and Cox proportional hazard models) were per-
formed. Potential confounders that were associated with
clinical outcome or abnormal glucose regulation with a
p-value <0.2, were included in the model. The following
risk factors were included in a stratification model; age,
gender, treated hypertension at admission, previous myo-
cardial infarction, smoking, body mass index, elevated tri-
glycerides and cholesterol, TnTmax, and infarct size
expressed as percent of ventricular mass. Adjustment for
the potential confounders identified by the model was per-
formed [17] and the follow-up time in patients years was
included. The STROBE guidelines were followed [18].
A two-sided p value <0.05 was considered statistically
significant. All analyses were performed using Epi-info
software, 2005, version 3.3.2.
Results
In-hospital OGTT was successfully performed in all
patients (n = 224) and categorised as described. As pre-
viously reported [10], the prevalence of abnormal glucose
regulation in-hospital was 47% (n = 105), of whom 24
patients (23%) (or 11% of the total population, n = 224)
were classified with newly detected type 2 diabetes.
The OGTT was repeated in 201 patients three months
after the acute STEMI. Twenty-three patients did not per-
form the repeated OGTT due to death (n = 1) or unwill-
ingness (n = 22). The 22 patients who were unwilling to
participate at three-month follow-up did, however, take
part in the interview by telephone in June 2009. Five out
of 22 patients reported a new clinical event during follow-
up, one patient within the first three months, and four
patients between three-month and (median time) 33
months follow-up. The number of patients with normal
and abnormal glucose regulation classified in-hospital was
9 and 13, respectively, and two out of five with a new clini-
cal event had abnormal glucose regulation. The prevalence
of abnormal glucose regulation in the total population at
three-month follow-up was reduced to 25% (n = 50), of
whom 10 patients (20%) (or 5% of the total population,
n = 201) were classified as having type 2 diabetes [10].
Clinical and biochemical characteristics
Clinical characteristics of the study population according
to the glucometabolic classification in-hospital and at
three-month follow-up are shown in Table 1. Notably,
patients with abnormal compared to normal glucose regu-
lation were older, a higher proportion were women, and
they had larger myocardial infarct size measured as % of
left ventricular mass three months later. Significantly
higher levels of HbA1c, insulin, proinsulin, and HOMA-IR
(measured in-hospital and at three-month follow-up) were
found in patients with newly detected abnormal glucose
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(Table 2).
When comparing patients with and without new clini-
cal events, there were no significant differences in clini-
cal or biochemical characteristics (data not shown).
Glucose lowering medication was not introduced in-
hospital or during the three-month follow-up period in
any of the patients.
Follow-up
The median follow-up time for clinical events was 33
months (27, 39). The long-term clinical outcome was
excellent with low event-rate. Of the total population (n =
224), 58 (26%) patients experienced a new clinical event
including 33 patients with recurrent ischemia. Six patients
died, two of myocardial re-infarction, one of cancer, one
of an infectious disease with multiorgan failure, and two
died without known reason. Fifteen patients experienced a
non-fatal re-infarction. Table 3 summarises all first events
in relation to the glucometabolic status classified in-
hospital.
The Kaplan-Meier curves for patients with normal (n =
119) or abnormal glucose regulation (n = 105) classified
by an OGTT in-hospital are shown in Figure 1A. The
probability of remaining free from a new clinical event
did not differ between the two groups (Log-Rank, p =
0.4). In a multivariate analysis adjusting for potential con-
founders the association remained non-significant
Table 1 Clinical characteristic of patients with STEMI according to glucometabolic classifications by an OGTT
in-hospital and after three months
In-hospital At three-month follow-up
NGR (n = 119) AGR (n = 105) P NGR (n = 151) AGR (n = 50) P
Age (years) 55 (50,63) 60 (54,71) <0.001 57 (51, 65) 61 (52, 72) 0.04
Men 106 (89.1) 79 (75.2) <0.01 129 (85.4) 36 (72.0) 0.03
Previous disorders
Treated dyslipidaemia 11 (9.2) 9 (8.6) 0.86 15 (9.9) 4 (8.0) 0.47
Treated hypertension 25 (21) 33 (31.4) 0.32 38 (25.2) 17 (34.0) 0.23
Previous acute MI 9 (7.6) 7 (6.7) 0.08 10 (6.6) 4 (8.0) 0.48
Previous angina pectoris 5 (4.2) 2 (1.9) 0.33 6 (4.0) 1 (2.0) 0.45
Current smoker 65 (54.6) 44 (41.9) 0.06 67 (44.4) 24 (48.0) 0.66
Body mass index (kg/m
2) 25.9 (24.5, 28.7) 26.1 (24.3, 28.6) 0.82 26.1 (24.4, 28.5) 25.7 (24.1, 28.7) 0.73
Waist circumference 100 (94, 107) 99 (94, 107) 0.86 101 (94, 107) 98 (94, 107) 0.92
Cholesterol (mmo/L) 5.2 (4.5, 5.8) 5.1 (4.4, 5.8) 0.52 4.1 (3.8, 4.6) 4.0 (3.6, 4.8) 0.43
LDL-cholesterol (mmol/L) 3.4 (2.7, 4.2) 3.3 (2.7, 4.0) 0.54 2.2 (1.8, 2.6) 2.1 (1.7, 2.6) 0.42
Triglycerides (mmo/L) 1.4 (1.0,1.8) 1.2 (0.9,1.8) 0.11 1.2 (0.9, 1.6) 1.2 (1.1, 1.6) 0.64
Stents 114 (95.8) 101 (96.2) 0.88 143 (94.7) 49 (98.0) 0.30
One-vessel disease 78 (65.5) 61 (58.1) 0.25 92 (60.9) 30 (60.0) 0.91
Left main disease 47 (39.5) 42 (40.0) 0.94 58 (38.4) 21 (42.0) 0.65
IIb/IIIa inhibitors 37 (31.1) 42 (40.0) 0.17 54 (35.8) 19 (38.0) 0.78
TnT peak value (ug/L) 4.47 (2.39, 7.32) 5.63 (2.78,10.89) 0.03 4.85 (2.45, 8.31) 4.97 (2.38, 10.25) 0.47
Measured at three-month.
LVEF
1 (%) 64 (57, 70) 62 (52,69) 0.13 63.5 (56, 70) 63.5 (51, 69) 0.47
Infarct size
2 (%) 9 (0, 25) 20 (4.5, 32) <0.001 13 (0, 27) 21.5 (0, 43) 0.04
Medication at discharge from CCU and after three months.
Aspirin 119 (100) 105 (100) 150 (99.3) 50 (100) 0.57
Clopidogrel 118 (99.2) 104 (99.0) 0.93 143 (94.7) 46 (92.0) 0.49
b-blockers 96 (80.7) 85 (81.0) 0.96 142 (94.0) 46 (92.0) 0.61
Lipid lowering agents 118 (99.2) 103 (99.1) 0.49 146 (96.7) 48 (96.0) 0.82
ACEIs 19 (16) 17 (16.2) 0.96 52 (34.4) 17 (34.0) 0.96
ARBs 8 (6.7) 10 (9.5) 0.44 21 (13.9) 4 (8.0) 0.27
Data are presented as median values (25, 75 percentiles) or proportions.
ACEIs: angiotensin-converting enzyme inhibitors, AGR: abnormal glucose regulation, acute MI: acute myocardial infarction, ARBs: angiotensin receptor blockers,
CCU: coronary care unit, NGR: normal glucose regulation, TnT peak level: serum peak level of cardiac specific Troponin T.
1,2Measured at three months by SPECT
analysis,
1LVEF: left ventricular ejection fraction,
2infarct size in % of left ventricular mass.
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1.38), p = 0.44).
Long-term prognosis was also compared between
groups of patients classified into normal (n = 151) and
abnormal glucose regulation (n = 50) based on an OGTT
performed in a stable condition at three-month follow-up.
No significant difference in survival free of composite end-
point was found between the groups (Figure 1B, Log-
Rank, p = 0.3). Adjusting for potential confounders did
not change the results significantly (adjusted HR 0.68
(95% CI 0.34-1.36), p = 0.27). Nine patients experienced a
new clinical event before the OGTT classification was per-
formed at three-month. Among these nine patients, seven
and two patients were classified into the abnormal and
normal glucose regulation group, respectively, based on
the in-hospital OGTT.
Discussion
Our main result was that stable STEMI patients without
previously known diabetes have an excellent long-term
prognosis independently of newly detected abnormal
glucose regulation made by an OGTT screening either
in-hospital or at three-month follow-up.
Large prospective studies have demonstrated both
admission and fasting blood glucose levels to be inde-
pendent predictors of long-term mortality in non-dia-
betic acute MI patients whether treated by primary
PCI or not [19-24]. However, data evaluating the prog-
nostic importance of an OGTT performed during or
early after an acute MI in patients without previously
known diabetes are scarce. The timing of testing
patients for abnormal glucose regulation after an acute
MI is also uncertain. Recommendation of early screen-
ing of acute MI patients with an OGTT in order to
detect high-risk patients in the recent European guide-
l i n e si sm a i n l yb a s e do nt h ef o l l o w - u ps t u d yo ft h e
GAMI trial [8,9]. In this follow-up study, abnormal
glucose regulation classified by an OGTT day four or
five post-MI was associated with worse clinical out-
come during a median follow-up time of about three
years [8].
Our study is the second study (after the GAMI study)
to evaluate early OGTT during an acute STEMI as a
prognostic tool, in patients without previously known
diabetes, and the first study who compared the prognos-
tic value of an OGTT based classification in-hospital
and after three months. The low event rate in the pre-
sent study prevents firm conclusions about the prognos-
tic value of OGTT screening in patients with acute
STEMI. There was a non-significant trend towards
increased hazard in patients with abnormal vs. normal
glucose regulation and a real difference between groups
may have been detected if the sample size was larger.
However, our results are not in line with the similar
sized GAMI study and may challenge the present guide-
lines, which emphasize the importance of early testing
of all patients with acute MI, especially in the modern
era of acute revascularization of STEMI patients.
Table 2 Biochemical variables in patients according to glucometabolic status classified by an OGTT in-hospital and at
three-month
NGR (in-hospital)
(n = 119)
AGR (in-hospital)
(n = 105)
P NGR (at three-month)
(n = 151)
AGR (at three-month)
(n = 50)
P
HbA1c (%) 5.5 (5.3, 5.7) 5.6 (5.4, 5.8) <0.01 5.5 (5.4, 5.7) 5.8 (5.5, 6.2) <0.0001
Insulin (pmol/L) 66 (46, 87) 73 (53,108) 0.03 63 (39, 82) 75 (47, 112) 0.02
C-peptid (pmol/L) 788 (638, 1026) 1026 (728, 1241) <0.001 834 (636, 1077) 893 (728, 1129) 0.11
Proinsulin (pmol/L) 6.8 (4.7, 10.4) 8.6 (5.8, 13.9) 0.02 5.4 (4.3, 8.5) 7.5 (5.4, 10.3) 0.01
HOMA-IR (mU mmol
-
1 L
-1)
2.45 (1.63, 3.36) 3.00 (2.11, 4.92) <0.001 2.20 (1.45, 3.23) 3.15 (2.08, 4.99) <0.01
Proinsulin: insulin
ratio
0.12 (0.08, 0.19) 0.13 (0.08, 0.18) 0.87 0.10 (0.07, 0.15) 0.12 (0.07, 0.18) 0.41
Data are presented as median values (25, 75 percentiles).
AGR: abnormal glucose regulation, NGR: normal glucose regulation.
Table 3 Number of first clinical events according to glucometabolic status classified by an OGTT in-hospital in patients
(n = 224) with STEMI
Type of event NGR (n = 119) IFG (n = 12) IGT (n = 69) DM (n = 24) Total
Death 1 1 4 0 6
Non-fatal re-infarction 9 0 5 1 15
Recurrent ischemia 20 0 8 5 33
Stroke 4 0 0 0 4
SUM 34 1 17 6 58
NGR: normal glucose regulation, IFG: impaired fasting glucose, IGT: impaired glucose tolerance, DM: type 2 diabetes mellitus.
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the low proportion of patients classified with type 2 dia-
betes in-hospital and at three-month (11% and 5%,
respectively). Nevertheless, patients classified with abnor-
mal compared to normal glucose regulation in-hospital
and at three-month follow-up had significantly higher
fasting values of HbA1c, circulating levels of insulin and
proinsulin, and higher HOMA-IR score when measured
both acutely and in a stable condition. These results cor-
respond to another trial with acute MI patients showing
that HbA1c and proinsulin were in the lowest range in
patients with normal glucose regulation, intermediate in
patients with impaired glucose tolerance, and highest in
patients with type 2 diabetes [25]. The present results
suggest that the abnormal glucose regulation found in
these STEMI patients not only seem to be a transient
stress-induced response, but also may be a result of
underlying insulin resistance.
The overall mortality rate in the present study was
2.7%. None died in-hospital and only one patient died
during the first 30 days. Nine patients (7 with abnormal
glucose regulation) experienced a new clinical event
before the OGTT classification was performed at three-
month follow-up. A low overall incidence of clinical
events was found during the first three months of follow-
up, suggesting that a early OGTT based classification of
the glucometabolic status in order to identify high risk
patients with worse prognosis is possibly of limited
importance in low risk patients with a primary PCI trea-
ted STEMI.
The low overall incidence of clinical events reported in
our study may partly be explained by the inclusion criteria.
Unstable patients with cardiogenic shock, renal failure,
ongoing chest pain, nausea and persistent hyperglycaemia
were excluded from the study, probably making a selection
bias towards more glucometabolically normal patients
with better prognosis.
Furthermore, the patients included were relatively
young and previous studies have shown a close relation-
ship between newly diagnosed abnormal glucose regula-
tion and age [8,26-28]. Additionally, a high proportion of
our patients were diagnosed with single-vessel disease
during coronary angiography [10], which may have con-
tributed to the low event-rate observed in both groups.
Systematic use of recommended treatment (evidenced
based medications and revascularisation) has been shown
to have a favourable impact on one-year prognosis in
patients with diabetes and coronary artery disease [29].
Patients in the present study were all treated by primary
PCI in addition to a high proportion of patients on evi-
dence based secondary prevention. All patients were trea-
ted according to guidelines regardless of glucometabolic
status and this may explain the excellent prognosis
observed in this STEMI population. Transient hypergly-
caemia in patients with acute MI without known diabetes
is common and is associated with worse outcome [19,24].
However, it has been difficult to prove that glucose con-
trol by insulin-glucose infusion [30] or insulin-glucose-
potassium infusion [31], improve survival in patients with
acute MI.
The European guidelines on diabetes, pre-diabetes, and
cardiovascular diseases recommend that patients with
cardiovascular disease without known diabetes should be
investigated with an OGTT [9], but whether the OGTT
should be performed early after a first cardiovascular
Figure 1 Kaplan-Meier curves, survival free of composite end-
point for patients with normal (NGR) and abnormal glucose
regulation (AGR) classified by an OGTT in-hospital (A) and after
three months (B).
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present results suggest that OGTT screening of patients
with acute STEMI without known diabetes should be
performed in a stable condition during the post-MI fol-
low-up.
Study limitations
The present study has certain limitations such as a possi-
ble selection bias towards more glucometabolically normal
patients due to the exclusion of patients who were hemo-
dynamically unstable, had severe renal failure and persis-
tent hyperglycaemia. Accordingly, patients included, were
somewhat younger than expected from a general STEMI
population, had relatively few comorbidities and mainly
one-vessel disease. It is possible that different results
would be obtained in older MI patients since high age has
been shown to be associated with ischemia related hyper-
glycaemia and poor glycemic control [28].
All aspects taken together may explain the overall low
incidence of clinical events during the follow-up period,
but may also reflect the advances in modern treatment of
STEMI with primary PCI in all patients and optimal
post-infarction treatment. The association between
abnormal glucose regulation classified by an OGTT and
clinical outcome should be further investigated in forth-
coming studies including primary PCI treated STEMI
patients, with a prolonged follow-up period, using major
cardiovascular events as a primary end-point.
Conclusions
Patients with a primary PCI treated STEMI, without pre-
viously known diabetes, appear to have an excellent long-
term prognosis, independent of the glucometabolic state
classified by an OGTT in-hospital or at three-month
follow-up.
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